We are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. Due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses.

Our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. We plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products.

Our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The lysins digest (or "lyse") the bacterial cell wall and are fundamentally different than antibiotics, in that they kill bacteria immediately upon contact. We believe the unique properties of our lysins make them suitable for the treatment of serious resistant infections such as Staphylococcus aureus ("Staph aureus", "Staph") bacteremia, pneumonia, osteomyelitis (infection of a bone), and biofilm-related indications for infected prosthetic joints, indwelling devices and catheters.

In addition to our lysins, we are exploring therapies using monoclonal antibodies that block and disarm virulence factors of bacteria and viruses, rendering them vulnerable to the natural immune balance of the body. Our most advanced products are CF-301, a lysin for the treatment of Staph aureus bacteremia and CF-404, a cocktail of monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza.